5th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

June 6th-8th, 2012
Durham, NC - USA
WASHINGTON DUKE INN HOTEL

www.focaltherapy.org
5th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

June 6th-8th, 2012
Durham, NC - USA

FINAL PROGRAM
Welcome

Dear Friends,

In June 2012 it will have been five years since the initiation of the First International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer. We wish to return to the site of the inaugural meeting and host the **Fifth International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer** at the Washington Duke Inn June 6-8, 2012, in Durham, North Carolina.

Much has transformed the landscape of prostate cancer over these last five years. To start, there has been a growing recognition of the over-treatment of prostate cancer, with now a shift towards expectant management prior to consideration of radical whole gland therapy for select men with early stage prostate cancer. This understanding bodes well for focal therapy, as we have positioned it to be a minimally-invasive treatment that destroys the known area(s) of cancer while preserving a man’s continence and potency. Today, there is growing interest in focal therapy for kidney and prostate cancers by physicians and patients alike.

At the recent Fourth International Symposium held in the Netherlands we also witnessed the confidence and enthusiasm for incorporating real-time imaging into the diagnostic and treatment strategy for prostate and kidney cancer.

We thank you for joining us in Durham this June 2012!

**Thomas J. Polascik, MD**
Professor of Surgery
Department of Surgery, Division of Urology
Duke University Medical Center
Durham, North Carolina, USA
**Symposium Planning Committee**

**Symposium Director**
- Dr. Thomas J. Polascik
  - Professor of Surgery
  - Department of Surgery
  - Division of Urology
  - Duke University Medical Center
  - Durham, North Carolina, USA

**Dr. Jean de la Rosette**
- Professor and Chairman,
  - Department of Urology
  - AMC University Hospital
  - Amsterdam, The Netherlands

**Dr. Inderbir Gill**
- Professor and Chairman
  - Department of Urology
  - University of Southern California
  - Los Angeles, USA

**Symposium International Program Committee**

**Dr. John Baust**
- Chair and Professor in the Departments of Biological Sciences
  - State University of New York
  - Binghamton, USA
  - *(Basic Sciences)*

**Dr. Arie Belldegrun**
- Professor of Urology
  - Chief of Urologic Oncology
  - UCLA, Los Angeles, USA
  - *(Society of Urologic Oncology (SUO) representative)*

**Dr. Rajan Gupta**
- MD, Radiologist
  - Duke University Medical Center
  - Durham, North Carolina, USA
  - *(Radiology)*

**Dr. J. Stephen Jones**
- Professor of Surgery (Urology)
  - Chairman Cleveland Clinic
  - Department of Regional Urology
  - Cleveland, USA

**Dr. Jaime Landman**
- Professor of Urology and Radiology
  - Chairman,
  - Department of Urology
  - University of California
  - Irvine, USA
  - *(Endourological Society representative)*

**Dr. Cary N. Robertson**
- Department of Surgery,
  - Division of Urology
  - Duke University Medical Center
  - Durham, North Carolina, USA
  - *(Technologies)*

**Dr. Matvey Tsivian**
- MD, Urologist
  - Department of Surgery
  - Division of Urology
  - Duke University Medical Center
  - Durham, North Carolina, USA

**Dr. Hessel Wijkstra**
- Principal Investigator
  - Department of Urology
  - Academic Medical Centrum
  - University of Amsterdam
  - Amsterdam, The Netherlands
  - *(EAU Section of Urological Imaging (ESUI) representative)*

**Dr. Pilar Laguna**
- Professor, Department of Urology
  - AMC University Hospital
  - Amsterdam - The Netherlands
  - *(EAU Section of Uro-Technology (ESUT) representative)*

**Dr. Cary N. Robertson**
- Department of Surgery,
  - Division of Urology
  - Duke University Medical Center
  - Durham, North Carolina, USA
  - *(Technologies)*

**Dr. Hessel Wijkstra**
- Principal Investigator
  - Department of Urology
  - Academic Medical Centrum
  - University of Amsterdam
  - Amsterdam, The Netherlands
  - *(EAU Section of Urological Imaging (ESUI) representative)*
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed Hashim</td>
<td>University College Hospital, London, UK</td>
</tr>
<tr>
<td>Boll Daniel</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Aron Monish</td>
<td>University of Southern California, Los Angeles, USA</td>
</tr>
<tr>
<td>Baust John</td>
<td>State University of New York, New York, USA</td>
</tr>
<tr>
<td>Belldegrun Arie</td>
<td>UCLA Institute of Urologic Oncology, Los Angeles, USA</td>
</tr>
<tr>
<td>Choyke Peter</td>
<td>Molecular Imaging Program NCI, Bethesda, USA</td>
</tr>
<tr>
<td>Coleman Jonathan</td>
<td>New York, USA</td>
</tr>
<tr>
<td>De la Rosette Jean</td>
<td>AMC University of Amsterdam, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>De Marzo Angelo</td>
<td>Predictive Biosciences &amp; The Johns Hopkins University School of Medicine, Baltimore, USA</td>
</tr>
<tr>
<td>Desai Mihir</td>
<td>University of Southern California, Los Angeles, USA</td>
</tr>
<tr>
<td>Donovan James</td>
<td>University of Cincinnati, Cincinnati, USA</td>
</tr>
<tr>
<td>Farokhzad Omid</td>
<td>Brigham and Women’s Hospital / Harvard Medical School, Boston, USA</td>
</tr>
<tr>
<td>Feleppa Ernest</td>
<td>Center for Biomedical Engineering, New York, USA</td>
</tr>
<tr>
<td>Feller John</td>
<td>Desert Medical Imaging, Indian Wells, CA, USA</td>
</tr>
<tr>
<td>Ferrandino Michael</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Fütterer Jurgen</td>
<td>UMC St. Radboud, Nijmegen, The Netherlands</td>
</tr>
<tr>
<td>George Daniel</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Gupta Rajan</td>
<td>Duke University Medical Center/Department of Radiology, Durham, USA</td>
</tr>
<tr>
<td>Jones J. Stephen</td>
<td>Cleveland Clinic foundation, Cleveland, OH, USA</td>
</tr>
<tr>
<td>Joniau Steven</td>
<td>University Hospitals Leuven, Leuven, Belgium</td>
</tr>
<tr>
<td>Katz Aaron</td>
<td>Winthrop University Hospital, New York, USA</td>
</tr>
<tr>
<td>Kim Charles</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Kirkham Alexander</td>
<td>University College Hospital, London, United Kingdom</td>
</tr>
<tr>
<td>Klingler Christoph-Hans</td>
<td>Medical University of Vienna, Vienna, Austria</td>
</tr>
<tr>
<td>Klotz Laurence</td>
<td>Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada</td>
</tr>
<tr>
<td>Kurhanewicz John</td>
<td>University of California UCSF, San Francisco, USA</td>
</tr>
<tr>
<td>Laguna Pilar</td>
<td>AMC University of Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Landman Jaime</td>
<td>University of California Irvine, Irvine, USA</td>
</tr>
<tr>
<td>Lee Benjamin</td>
<td>University School of Medicine, New Orleans, USA</td>
</tr>
<tr>
<td>Leveillee Raymond</td>
<td>University of Miami-Hospitals and Clinics-Miller School of Medicine, Miami, FL, USA</td>
</tr>
<tr>
<td>Marberger Michael</td>
<td>Medical University of Vienna, Department of Urology, Vienna, Austria</td>
</tr>
<tr>
<td>Meier James</td>
<td>Baylor University Medical Center, Baylor, USA</td>
</tr>
<tr>
<td>Moul Judd</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Nightingale Kathy</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Pinto Peter</td>
<td>National Cancer Institut, Bethesda, USA</td>
</tr>
<tr>
<td>Polascik Thomas</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Preminger Glenn</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Rampersaud Edward</td>
<td>UCLA Institute of Urologic Oncology, Los Angeles, USA</td>
</tr>
<tr>
<td>Robertson Cary</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Singleton Bruce</td>
<td>Georgia Health Sciences University, Augusta, USA</td>
</tr>
<tr>
<td>Sivaraman Ananth</td>
<td>Global Robotics Institute, Orlando, USA</td>
</tr>
<tr>
<td>Sopko David</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Trachtenberg John</td>
<td>Princess Margaret Hospital, University of Toronto, Toronto, Canada</td>
</tr>
<tr>
<td>Tsivian Matrey</td>
<td>Duke University Medical Center, Durham, USA</td>
</tr>
<tr>
<td>Ukimura Osamu</td>
<td>University of Southern California, Norris Cancer Center, Los Angeles, USA</td>
</tr>
<tr>
<td>Verma Sadhna</td>
<td>University of Cincinnati, Cincinnati, USA</td>
</tr>
<tr>
<td>Villers Arnauld</td>
<td>Lille 2 University-Hôpital Huriez, Lille France</td>
</tr>
<tr>
<td>Wijkstra Hessel</td>
<td>AMC University of Amsterdam, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Wong Jaime</td>
<td>Jenkins Clinic, Georgia, USA</td>
</tr>
</tbody>
</table>
CME Information

DUKE Urology, a Division of the Department of Surgery
presents 5th International Symposium on Focal Therapy and Imaging in Prostate and Kidney Cancer

Commercial Support Acknowledgement
This CME activity is supported by educational grants from AMGEN, ANGIODYNAMICS, BRACCO SUISSE, ETHICON, GALIL, HEALTHTRONICS, HISTOSCANNING, INVIVO, STEBA, UC-CARE, and US HIFU.

Statement of Need
Much has transformed the landscape of prostate cancer over the past five years. There has been a growing recognition of the over-treatment of prostate cancer, with a shift towards expectant management prior to consideration of radical whole gland therapy for select men with early stage prostate cancer. This understanding bodes well for focal therapy, a minimally invasive treatment that destroys the known area(s) of cancer while potentially preserving a man’s continence and potency. Today, there is a confidence and enthusiasm for incorporating real-time imaging into the diagnostic and treatment strategy for prostate and kidney cancer.

Target Audience
This symposium is designed for urologists, radiation oncologists, radiologists, medical oncologists, uropathologists, biomedical engineers, as well as other health care professionals, scientists, and investigators.

Learning Objectives
At the conclusion of this activity, participants should be able to:
• Review, compare and contrast the current modern technological advancements in treatments for localized prostate and kidney cancer and their outcomes.
• Examine the modern imaging techniques for prostate and kidney cancer and assess their value in diagnosis and image-guided treatment.
• Appraise the modern management strategies for prostate and kidney cancer, including ablative technologies and active surveillance, evaluate appropriate candidates and assess potential treatment failures and their management.

Faculty Listing
See pages 4-5 for a complete listing of the faculty.

Staff and Content Validation Reviewer Disclosure
The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.

Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
Planning Committee/Faculty Disclosure
Any relationships with industry reported by the symposium planning committee members and speakers are included with the CME Credit Attestation Form hand-out.

Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Agenda
See pages 8-15 for the complete symposium agenda.

Unapproved Use Disclosure
Duke School of Medicine requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. Off label topics include but are not limited to discussions on how imaging modalities can or cannot detect stage and grade cancer, any use of a drug or device for the focal treatment of cancer, use of medical therapy to treat or potentially prevent cancer, use of diagnostic tests to make predictions on the nature and aggressiveness of cancer.

Accreditation
The Duke University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The Duke University School of Medicine designates this educational activity for a maximum of 20.5 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

How to Receive Credit
In order to receive CME credit, participants must sign-in, review the CME information in the program, attend the CME activity, and complete and submit the attestation form to the registration desk. Following the symposium participants should complete the on-line evaluation survey. A certificate of credit will be e-mailed to the requesting participant within 8 weeks of receipt of the completed attestation form. (Please confirm we have the correct email address to ensure you will receive your certificate.)

Special Needs Statement
The Duke Division of Urology is committed to making its activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing in order to receive service.
Scientific Program

Wednesday, June 6, 2012

10:00-18:00 Registration

13:30-15:30 Poster Session 1: Prostate imaging
Moderators: Rajan Gupta - John Kurhanewicz - Alexander Kirkham
Posters No P1-P19 (see details on pages 16-17)

13:30-15:30 Poster Session 2: Prostate treatment
Moderators: Thomas Polascik - Jurgen Futterer - Edward Rampersaud
Posters No P20-P37 (see details on pages 17-19)

13:30-15:30 Poster Session 3: Kidney imaging and treatment
Moderators: Steven Joniau - Bruce Shingleton - Mat Tsivian
Posters No K01-K09 (see details on page 19)

15:30-15:45 Coffee Break

15:45-16:30 Lecture: XGEVA (denosumab) and Prostate Cancer: Identifying Bone Metastases and Preventing Skeletal-Related Events
Judd Moul, Durham, USA
Cordially supported by AMGEN
Not a Duke-sponsored nor CME credit source

16:30-18:00 Video Session: This is how I do it
Moderator: Thomas Polascik

MRI Guided Focal Laser Ablation of Localized Prostate Cancer (7’45’’)
Dmitry Volkin (USA)
Wednesday, June 6, 2012

Focused ultrasound ablation under MRI-guidance in the treatment of patients with low-risk localized prostate cancer (4'50")
Alexander Nosov (Russia)

Smart Biopsy - fulfilling my wishes (12'00")
Michael Cohen (Israel)

MR Guided Prostate Procedure (9'45")
Jurgen Fütterer (USA)

3D TRUS Prostate biopsies mapping and MRI fusion: Concept and first clinical results (8'00")
Pierre Mozer (France)

Not a Duke-sponsored nor CME credit source

18:00-18:30 Opening Ceremony

18:30 Welcome Reception
Thursday, June 7, 2012

**KIDNEY CANCER PROGRAM**  
**HALL A: Presidents I & II**

07:30-09:45 **Session 1: Imaging and new concepts**  
Moderators: James Meler - Raymond Leveillee - Christoph Klingler

- 07:30-07:40 Welcome & renal program overview  
  Thomas Polascik (Durham, USA)

- 07:40-07:55 Quantitative characterization of renal tumors on CT  
  Mihir Desai (Los Angeles, USA)

- 07:55-08:10 The *Endourological Society* lecture: Role of active surveillance  
  Jaime Landman (Irvine, USA)

- 08:10-08:25 Should biopsy of the small renal mass be a standard of care?  
  Pilar Laguna (Amsterdam, The Netherlands)

- 08:25-08:40 Fusion ultrasound: The future of image-guided renal therapy?  
  Bruce Shingleton (Augusta, USA)

- 08:40-08:55 The *EAU Section of Urological Imaging (ESUI)* lecture: Monitoring the effect of renal ablation and antiangiogenic therapy with CEUS  
  Hessel Wijkstra (Amsterdam, The Netherlands)

- 08:55-09:10 The *Society of Urologic Oncology (SUO)* lecture: Neoadjuvant cancer ablation to enhance active immunotherapy  
  Arie Belldegrun (Los Angeles, USA)

- 09:10-09:45 Panel discussion

09:45-10:15 Coffee Break

10:15-12:00 **Session 2: Technologies: Efficacy, morbidity, costs**  
Moderators: Jaime Landman - Benjamin Lee - David Sopko

- 10:15-10:30 Percutaneous and laparoscopic cryoablation: 10 year data  
  Monish Aron (Los Angeles, USA)

- 10:30-10:45 Update on utility of renal HIFU  
  Christoph Klingler (Vienna, Austria)
**Thursday, June 7, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:45-11:00| *Percutaneous low energy direct current (IRE)*  
James D. Meler (Houston, USA) |
| 11:00-11:15| *Alternative energy sources: What's on the horizon*  
Raymond Leveillee (Miami, USA) |
| 11:15-11:30| *Advances in partial nephrectomy: Zero-ischemia technique*  
Inderbir Gill (Los Angeles, USA) |
| 11:30-12:00| Round table discussion: *Patient selection - AS, ablate, resect?*  |

**12:00-13:00**  
**Lunch Session**  
*Radiation Recurrent Prostate Cancer - Salvage Cryotherapy Offers Patients, a Curative Treatment Option*  
Aaron Katz and Philippa Cheetham  
*Cordially supported by Galil Medical  
Not a Duke-sponsored nor CME credit source*

**HALL A: Presidents I & II**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:00-14:30| **Session 3: Post treatment surveillance**  
Moderators: Monish Aron - Michael Marberger  
*Post ablation enhancement: Definitions, implications, role of biopsy*  
Charles Kim (Durham, USA)  
*Post ablation surveillance: Managing radiation exposure*  
Michael Ferrandino (Durham, USA)  
**The EAU Section of Uro-Technology (ESUT) Lecture:** Interpreting EAU and AUA guidelines for the small renal mass  
Steven Joniau (Leuven, Belgium)  
*How to start a focal renal program*  
Benjamin Lee (New Orleans, USA)  
Panel discussion |
| 14:25-14:30| Close of kidney program  
Pilar Laguna (Amsterdam, The Netherlands) |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-16:25</td>
<td><strong>Session 4: Foundation for focal therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> Arnauld Villers - Aaron Katz - Angelo De Marzo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30-14:40</td>
<td>Welcome</td>
<td>Jean de la Rosette</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>14:40-14:55</td>
<td>Biological characterization of the Index lesion</td>
<td>Hashim Uddin Ahmed</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>14:55-15:10</td>
<td>Nanomedicines for diagnosis and treatment of PCa</td>
<td>Omid Farokhzad</td>
<td>Boston, USA</td>
</tr>
<tr>
<td>15:10-15:25</td>
<td>Role of focal therapy in the treatment armamentarium</td>
<td>Cary Robertson</td>
<td>Durham, USA</td>
</tr>
<tr>
<td>15:25-15:40</td>
<td>Patient Selection</td>
<td>J. Stephen Jones</td>
<td>Cleveland, USA</td>
</tr>
<tr>
<td>15:40-15:55</td>
<td>A rational sampling strategy for focal therapy</td>
<td>Hashim Uddin Ahmed</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>15:55-16:25</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:25-16:45</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45-18:15</td>
<td><strong>Session 5: New concepts in FT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> Judd Moul - Peter Pinto - James Donovan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>The American College of Cryosurgery (ACC) lecture: Hallmarks of cancer</td>
<td>John Baust</td>
<td>Binghamham, USA</td>
</tr>
<tr>
<td></td>
<td>and thermal ablative therapies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>Biomarkers to improve risk assessment</td>
<td>Angelo De Marzo</td>
<td>Baltimore, USA</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>Chemoprevention and adjuncts</td>
<td>Daniel George</td>
<td>Durham, USA</td>
</tr>
<tr>
<td>17:45-18:15</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Friday, June 8, 2012**

### PROSTATE CANCER PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30-10:00</td>
<td><strong>Session 6: Role of ultrasound in diagnosis and targeting</strong></td>
</tr>
<tr>
<td></td>
<td>Moderators: TBA - Peter Choyke</td>
</tr>
<tr>
<td>07:30-07:45</td>
<td>Targeted ultrasound bubbles for targeted therapies</td>
</tr>
<tr>
<td></td>
<td>Hessel Wijkstra (Amsterdam, The Netherlands)</td>
</tr>
<tr>
<td>07:45-08:00</td>
<td>Acoustic Radiation Force Impulse (ARFI) imaging of prostate</td>
</tr>
<tr>
<td></td>
<td>Kathy Nightingale (Durham, USA)</td>
</tr>
<tr>
<td>08:00-08:15</td>
<td>Targeted US-MRI fusion</td>
</tr>
<tr>
<td></td>
<td>Peter Pinto (Bethesda, USA)</td>
</tr>
<tr>
<td>08:15-08:30</td>
<td>Elastic (non-rigid) MR-US fusion targeted biopsy</td>
</tr>
<tr>
<td></td>
<td>Inderbir Gill (Los Angeles, USA)</td>
</tr>
<tr>
<td>08:30-08:45</td>
<td>Real time ultrasound monitoring of tissue changes</td>
</tr>
<tr>
<td></td>
<td>Michael Marberger (Vienna, Austria)</td>
</tr>
<tr>
<td>08:45-09:00</td>
<td>RF spectral analysis of prostate ultrasound</td>
</tr>
<tr>
<td></td>
<td>Ernest Feleppa (New York, USA)</td>
</tr>
<tr>
<td>09:00-09:15</td>
<td>Update on Histoscanning</td>
</tr>
<tr>
<td></td>
<td>Ananthakrishnan Sivaraman (Orlando, USA)</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>Real-time TRUS based 3D mapping</td>
</tr>
<tr>
<td></td>
<td>Osamu Ukimura (Los Angeles, USA)</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Panel discussion</td>
</tr>
</tbody>
</table>

#### HALL A: Presidents I & II

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture: Why Prostate MRI?</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:30</td>
<td>Sadna Verma and Bernadette Greenwood</td>
</tr>
<tr>
<td></td>
<td>Cordially supported by Invivo</td>
</tr>
<tr>
<td></td>
<td>Not a Duke-sponsored nor CME credit source</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Coffee Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:45</td>
<td></td>
</tr>
</tbody>
</table>
### Session 7: Role of MRI

**Moderators:** Sadhna Verma - John Feller - Daniel Boll

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45-11:00</td>
<td>How I use MRI in prostate cancer practice</td>
<td>Peter Choyke</td>
<td>Bethesda, USA</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>What MRI can see and what it cannot</td>
<td>Arnauld Villers</td>
<td>Lille, France</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Image-guided diagnosis and follow-up</td>
<td>Alex Kirkham</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>MRI spect</td>
<td>John Kurhanewicz</td>
<td>San Francisco, USA</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>What does MRI need to do to become standard of care?</td>
<td>Jurgen Fütterer</td>
<td>Nijmegen, The Netherlands</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Starting an MRI program in focal therapy</td>
<td>Rajan Gupta</td>
<td>Durham, USA</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>Endourethral MRI guided ablation with MRI thermometry</td>
<td>Laurence Klotz</td>
<td>Toronto, Canada</td>
</tr>
<tr>
<td>12:30-12:45</td>
<td>Robotic image-guided focal laser therapy</td>
<td>John Trachtenberg</td>
<td>Toronto, Canada</td>
</tr>
<tr>
<td>12:45-13:15</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Lunch Session

**Renal Cryoablation: Freeze It and Forget It**

Michael Fabrizio

*Cordially supported by Endocare
Not a Duke-sponsored nor CME credit source*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:15-16:45</td>
<td>Session 8: Targeted therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> Michael Marberger - Thomas Polascik - James Donovan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:15-14:30</td>
<td>Summary of Consensus Group II report on MRI</td>
<td>Jean de la Rosette (Amsterdam, The Netherlands)</td>
<td></td>
</tr>
<tr>
<td>14:30-14:45</td>
<td>MRI-guided biopsy: Ready for prime time?</td>
<td>Sadhna Verma (Cincinnati, USA)</td>
<td></td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>Transrectal MRI guided laser ablation</td>
<td>John Feller (Indian Wells, USA)</td>
<td></td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Focal cryoablation</td>
<td>J. Stephen Jones (Cleveland, USA)</td>
<td></td>
</tr>
<tr>
<td>15:15-15:30</td>
<td>How does focal compare to whole gland cryotherapy in the salvage setting?</td>
<td>Aaron Katz (New York, USA)</td>
<td></td>
</tr>
<tr>
<td>15:30-15:45</td>
<td>Focal low energy direct current (IRE)</td>
<td>Jaime Wong (Georgia, USA)</td>
<td></td>
</tr>
<tr>
<td>15:45-16:00</td>
<td>Focal HIFU update on phase I/II studies</td>
<td>Hashim Uddin Ahmed (London, United Kingdom)</td>
<td></td>
</tr>
<tr>
<td>16:00-16:15</td>
<td>Photodynamic therapy (TOOKAD® Soluble VTP). From bench to bedside</td>
<td>Jonathan Coleman (New York, USA)</td>
<td></td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Panel discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>Closing remarks and announcement of the 6th Focal Therapy Symposium</td>
<td>Jean de la Rosette (Amsterdam, The Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>
**Poster Presentations**

**Session I: Prostate imaging**

**P-01** Small-volume unilateral prostate cancer estimation results (super) score to aid candidate selection for focal therapy: Development and validation

**P-02** Rigid and non-rigid registration of prostate B-mode and ARFI images to MR and whole-mount histology

**P-03** The impact of saturation biopsy in decision making for low risk prostatic carcinoma after prior positive biopsy
R. Sanchez-Salas, N. Miranda, R. Valero, M. Sanchez-Encinas, A. Ouzzane, M. Galiano, F. Rozet, E. Barret, X. Cathelineau (France)

**P-04** Magnetic resonance imaging guided transperineal prostate needle biopsy in patients without a rectum

**P-05** Multi-parametric MRI and subsequent MR/ultrasound fusion biopsy increases the detection of anteriorly located prostate cancers

**P-06** Prostatic swelling and shift of intra-prostatic target during HIFU: Implication for targeted focal therapy
S. Shoji, T. Uchida, N. Masahiko, A. Abreu, S. Leslie, Y. Sato, I. Gill, O. Ukimura (USA & Japan)

**P-07** Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detects prostate cancer in patients with prior negative TRUS biopsies

**P-08** Low suspicion lesions on multiparametric magnetic resonance imaging do not correlate with high risk prostate cancer

**P-09** Value of targeted biopsy in detecting prostate cancer using an office-based MR-US fusion device
G.A. Sonn, S. Natarajan, D.J.A. Margolis, M. Macairan, P. Lieu, J. Huang, F.J. Dorey, L.S. Marks (USA)
P-10 Targeted prostatic biopsy based on multiparametric magnetic resonance imaging to select candidates for focal therapy of prostate cancer
K. Kamoi, K. Okihara, T. Iwata, F. Hongo, O. Ukimura, A. Kawauchi, T. Miki (Japan & USA)

P-11 High diagnostic yield achieved by targeting multiparametric magnetic resonance imaging-suspicious lesion using MRI/Ultrasound fusion guided prostate biopsy
K. Kamoi, K. Okihara, T. Iwata, F. Hongo, T. Ueda, A. Kawauchi, T. Miki (Japan)

P-12 Image fusion of the preoperative biopsy-proven 3D cancer model and the intraoperative 3D cryolesion: Assessment of therapeutic adequacy in lesion-targeted cryotherapy for prostate cancer
M. Nakamoto, O. Ukimura, N. Fukuda, S. Shoji, A.L.C. Abreu, S. Leslie, Y. Sato, I.S. Gill (USA, Japan)

P-13 Can multiparametric MRI accurately detect local prostate cancer recurrence in patients treated with radiotherapy, before focal salvage therapy?
M.A. Alazeez, H. Ahmed, E. Anastasiadis, M. Arya, A. Freeman, C. Allen, A. Kirkham, M. Emberton (United Kingdom)

P-14 Approaches for overcoming challenges of MRI-guided biopsy of prostate
J. Yu, A.S. Fulcher, M.A. Turner, C. Cockrell (USA)

P-15 Diagnosis of anterior prostate cancer using MRI/TRUS real time soft image fusion
E. Baco, E. Rud, A. Svindland, H.B. Eggesbø (Norway)

P-16 Comparison between systematic and MRI targeted prostate biopsy for patient with no history of prostate cancer attending a first round of trans-rectal ultrasound biopsy procedure
P. Mozer, G. Coffin, G. Chevreau, R. Renard-Penna, E. Compérat, M.-A. Vitrani, C. Torterotot, P. Conort, M.-O. Bitker (France)

P-17 Is a high strength (3Tesla) MRI scan necessary for the detection and characterisation of prostate cancer?
N.L. Robertson, C.M. Moore, M. Emberton (United Kingdom)

P-18 MAPPED - Prevalence of MRI detectable lesions in low-intermediate risk prostate cancer
Nicola L. Robertson, Caroline M. Moore, Mark Emberton (United Kingdom)

P-19 NADiA ProsVue: A prognostic test for identifying men at a reduced risk for prostate cancer recurrence following radical prostatectomy
J. Moul, R. Lance, J. Alter, M. Sarno, J. McDermed (USA)

Session 2: Prostate treatment

P-20 Morbidity of focal therapy in the treatment of localized prostate cancer
R. Sanchez-Salas, E. Barret, A. Ouzzane, R. Valero, M. Sanchez-Encinas, F. Rozet, M. Galiano, D. Prapotnich, X. Cathelineau (France)

P-21 Focal therapy of prostate cancer: Initial experience with cryotherapy
R. Sanchez-Salas, E. Barret, M. Galiano, R. Valero, M. Sanchez-Encinas, N. Miranda, F. Rozet, D. Prapotnich, X. Cathelineau (France)
P-22  Comparative evaluation of acute retention of urine in groups of patients with prostate cancer treated with high power and low power brachytherapy
A.U. Pavlov, I.A. Albitski, A.D. Tsibulski, K.N. Milenin, A.V. Shestakov (Russia)

P-23  Medium term outcomes following primary focal therapy using HIFU for localised prostate cancer
L. Dickinson, H. Ahmed, N. McCartan, A. Freeman, A. Kirkham, C. Allen, R. Hindley, M. Emberton (United Kingdom)

P-24  MRI guided prostate cancer focal ablation using HIFU by means of image to image registration

P-25  Salvage cryotherapy of the prostate: Long-term clinical, functional, and biochemical outcomes in a large cohort at a tertiary referral center
S. Wenske, A. E. Katz (USA)

P-26  Third generation total cryoablation as primary treatment for organ confined prostate cancer
H. Riemschneider, E. Hong (USA)

P-27  Magnetic resonance guided intra-urethral high intensity focused ultrasound treatment of prostate tissue in preclinical model

P-28  Efficacy of low temperature-sensitive liposome encapsulated docetaxel compared to free docetaxel in a xenograft murine model of prostate cancer

P-29  Histotripsy of ACE-1 implanted prostate tumor: Focal therapy in a canine model

P-30  The focal laser effects of treatment during interstitial laser coagulation in patients with prostate cancer
O. Teodorovich, A. Teplov, A. Bogoslavskiy, S. Naryshkin, G. Borisenko, Y. Andreeva, E. Rasshupkina, D. Kochiev (Russia)

P-31  Focal radio-frequency ablation for low-risk, focal prostate cancer: Challenges and technique
J.M. Pow-Sang, M. Biagioli, E. Outwater, S. Dickinson, S. Rao (USA)

P-32  Salvage focal vs salvage total cryoablation for radio-recurrent prostate cancer: 7 years experience

P-33  Prospective phase I trial of differential dose prostate brachytherapy guided by cancer-specific tissue-type imaging (TTI) and ultrasound spectrum analysis (USA): Preliminary dosimetric and clinical results
R. Ennis, F. Trichter, A. Jain, D. Goltz, J. Ostenson, E. Feleppa (USA)

P-34  Hemi salvage HIFU in patients with radiorecurrent prostate cancer
E. Baco, S. Crouzet, E. Rud, O. Rouviere, J.-Y. Chapelon, V. Berge, A. Gelet (Norway & France)
P-35  Delayed radical prostatectomy in intermediate-risk prostate cancer is associated with biochemical recurrence: Results from the SEARCH Database
A. Michael, A. William, T. Martha, K. Christopher, P. Joseph, A. Christopher, F. Stephen

P-36  Focal treatment of prostate cancer with HIFU
S. Crouzet, A. Villers, P. Rischmann, G. Pasticier, D. Hevallier, O. Rouviere, A. Gelet (France)

P-37  Preliminary results of a phase I trial using magnetic resonance-guided focused ultrasound surgery (MRgFUS) for the treatment of patients with locally-confined low-risk prostate cancer
A. Nosov, C. Cheng, S. Kanaev, G. Gafton, V. Turkevich, A. Vorobiev (Russia & Singapore)

Session 3: Kidney imaging & treatment

K-01  Renal mass anatomical characteristics and perioperative outcomes of laparoscopic partial nephrectomy: A critical analysis
M. Tsivian, S. Ulusoy, M.R. Abern, A. Wandel, A.A. Sidi, A. Tsivian (USA & Israel)

K-02  Impact of probe angulation on cryoablation zone geometry
Jun Yoo, Joshua Bryant, Charles Kim, Rendon Nelson (USA)

K-03  Renal function outcomes in patients with reduced nephron mass undergoing percutaneous renal cryoablation

K-04  Nd:Yag laser focal effect of localized kidney tumor
S. Naryshkin, O. Teodorovich, G. Borisenko, E. Rasshupkina, A. Ryazancew, D. Kurochkin, D. Kochiev (Russia)

K-05  Nd:YAG interstitial laser coagulation in vivo: Histopathologic analysis of the renal parenchima in different times after effect
E.V. Rasshchupkina, O.V. Teodorovich, G.G. Borisenco, S.A. Naryshkin, D.G. Kochiev (Russia)

K-06  7-year experiences with radiofrequency ablation for small renal masses
F. Vandercruysse, T. Meert, L. De Wever, F. Claus, R. Oyen, H. Van Poppel, S. Joniau (Belgium)

K-07  Zero-ischemia robotic partial nephrectomy: Striving for the trifecta

K-08  Modern hemostatic dressings improve the surgical procedure in murine kidney melanoma and renal cell adenocarcinoma animal models
M. Nowacki, A. Jundzill, M. Bieniek, T. Kowalczyk, S.L. Habib, T. Drewa (Poland & USA)

K-09  Anthropometric Renal Alterations Between Supine and Prone Positions in Percutaneous Renal Ablation for Renal Cortical Neoplasms
A. Lusch, S. Fujimoto, M.A. Liss, L.K. Findeiss, R. Clayman, J. Landman (USA)
Commercial Supporters

Platinum Level

GALIL MEDICAL

Gold Level

HealthTronics

Silver Level

AMGEN

AngioDynamics®

Bronze Level

HistoScanning

Invivo

USHIFU

Other Supporters

BRACCO

Ethicon

Medtronic

Steba Biotech

UC-Care Medical Systems

Exhibitors

AMGEN Inc

ANGIODYNAMICS

CIVCO MEDICAL SOLUTIONS

EDAP-TMS FRANCE

EIGEN

ELEKTA Inc

FERRING PHARMACEUTICAL

GALIL MEDICAL

HEALTHTRONICS

HISTOSCANNING

HITACHI ALOKA MEDICAL

KOELIS

PHILIPS HEALTHCARE

PREDICTIVE BIOSCIENCES INC

UC-CARE MEDICAL SYSTEMS Ltd

US HIFU
• Endocare™ Cryoablation
• Lithotripsy and Laser Services
• Laboratory Solutions
• UroChartEHR® and meridianEMR™ Electronic Medical Records Systems
• Physician Partnership Opportunities

888.252.6575
www.healthtronics.com
Think Curative

Salvage Cryotherapy

Curative Therapy
Without Hormone Side Effects

GALIL MEDICAL

Thursday, June 7th at 12pm

Radiation Recurrent Prostate Cancer-
Salvage Cryotherapy Offers Patients a Curative Treatment Option

Presenters: Aaron Katz, MD and Philippa Cheetham, MD